Qiagen N.V.
Every calculator, already run for QGEN
Open the full toolkit →You have the numbers on QGEN. Get the argument.
A written report on which of these readings actually decide the outcome for Qiagen N.V., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
12 analysts covering QGENAnalyst Price Target Disagreement for Qiagen N.V.
Wall Street's bull case implies +9% from the current price; the bear case implies -21%. Analysts are relatively aligned on QGEN's range.
Ownership & short interest
Insider Trading Activity for QGEN
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Qiagen N.V.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and as…
QGEN — frequently asked
Is QGEN a buy right now?
Wall Street's consensus rating on Qiagen N.V. is Hold across 12 analysts, with a mean price target of $49.20 (-2% vs. the current $50.37). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is QGEN overvalued?
QGEN trades at 25.6x trailing earnings, against a DCF fair value of $56 per share. The current price implies 5% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is QGEN's next earnings date?
Qiagen N.V. is next scheduled to report earnings around Nov 4, 2026. A full QGEN research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Qiagen N.V.?
Analysts covering Qiagen N.V. (QGEN) range from a bear-case target of $40.00 to a bull-case high of $55.00, with a mean consensus target of $49.20 across 11 analysts. The spread of $15.00 (30% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Qiagen N.V. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Qiagen N.V.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full QGEN research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Qiagen N.V., in minutes. 3 free reports included with every account — no credit card required.